#Netherlands #Sobi #Rotterdam #Gamifant #HLH

Sobi to Showcase New Findings on Gamifant® at Histiocyte Society 2026

Sobi® (Swedish Orphan Biovitrum AB) is all set to present groundbreaking clinical data on Gamifant® (emapalumab) at the upcoming Histiocyte Society 2026 Annual Meeting, scheduled from September 26 to 29 in Rotterdam, the Netherlands. This event is significant as it will highlight the latest advancements in the treatment of primary haemophagocytic lymphohistiocytosis (HLH), a rare but life-threatening condition characterized by severe hyperinflammation.

The data to be presented includes a comprehensive pooled analysis of survival outcomes before and after transplants, derived from three prospective trials. Two sessions will revisit earlier analyses on primary HLH, alongside findings from a post-authorisation study focusing on treatment options available for Chinese patients. Dr. Lydia Abad-Franch, the Chief Medical Officer at Sobi, expressed optimism about these developments, emphasizing that the continued research into treatment and transplantation outcomes in primary HLH is crucial for impacting the lives of patients suffering from this condition. The pooled-analysis has achieved recognition, being selected among the top ten poster abstracts for the coveted Robert J. Arceci Prize for Best Poster, a testament to its scientific importance.

Poster Presentations Scheduled

During the Poster Pitch Session on September 29, several pivotal studies related to Gamifant® will be discussed:

• - Pre- and Post-Transplant Survival: This presentation will explore the pooled analysis of Emapalumab in outcomes across prospective trials NI-0501-04, NI-0501-05, and NI-0501-09, shedding light on its effectiveness in treating primary HLH.
• - Rapid Response in Patients: Another poster will report on how Emapalumab facilitates quick and durable responses in patients with primary HLH, possibly acting as a bridge to curative HSCT (Hematopoietic Stem Cell Transplant).
• - Sustained Benefits Across Subgroups: Evidence will also be shared on how Emapalumab provides rapid and lasting benefits regardless of prior treatments or central nervous system involvement in patients with primary HLH.
• - Post-Authorization Study Insights: The findings from a post-authorization study will assess safety and efficacy in treatment-experienced primary HLH patients, particularly those from China, outlining the therapeutic potential and outcomes in a different patient demographic.

Understanding Gamifant® (Emapalumab)

Gamifant® (emapalumab) is a unique anti-interferon gamma monoclonal antibody that functions by binding to and neutralizing interferon gamma, which plays a role in the hyperinflammatory processes observed in HLH. Its administration is typically via intravenous infusion over one hour. This medication has received approval for both adult and pediatric patients suffering from refractory, recurrent, or progressive HLH and has shown promise in cases associated with Still's disease when other treatments have failed.

The Impact of Sobi®

Sobi is a renowned biopharmaceutical company committed to advancing innovative treatments that can significantly improve the quality of life for individuals battling rare diseases. With a workforce of about 2000 employees scattered across various regions, including Europe, North America, the Middle East, Asia, and Australia, Sobi has demonstrated impressive financial performance with revenues reaching SEK 28 billion in 2025. The company's dedication to innovation in healthcare is evident through its ongoing research and development efforts.

In summary, the presentation of clinical data related to Gamifant® at the Histiocyte Society 2026 is poised to deliver promising insights into the treatment of primary HLH, potentially ushering in a new era of therapeutic options for affected patients worldwide.